Elevate Your
Stock Analysis

→

$110.9B

Acquisition

Paramount → Warner Bros. Discovery

Media / Entertainment

WBD shareholders approved Paramount Skydance's $111 billion takeover on 23 April 2026 with an overwhelming 1.743 billion votes in favour. The deal — valued at $31 per WBD share in cash — still requires DOJ and FCC clearance. The EU completed Phase 1 antitrust review on 29 April 2026. Paramount disclosed that the combined company will be 49.5% owned by Middle Eastern sovereign wealth funds: Saudi PIF (15.1%), UAE sovereign fund (12.8%), and Qatar Investment Authority (10.6%), drawing FCC Commissioner scrutiny and prompting multiple state AGs to issue subpoenas. Paramount has filed a Section 310(b)(4) FCC petition for the foreign ownership stake. Close is targeted for Q3 2026, though regulatory complexity — DOJ, FCC, multiple state AG investigations — could push this to Q1 2027.

→

$85B

Merger

Union Pacific → Norfolk Southern

Transportation / Infrastructure

Union Pacific's proposed acquisition of Norfolk Southern would create the first transcontinental freight railroad in US history — combining Union Pacific's 32,000-route-mile western system with Norfolk Southern's 19,500-route-mile eastern network. The $85 billion combined enterprise value makes this the largest proposed railroad merger since Burlington Northern Santa Fe in 1995, with management projecting $1 billion per year in cost synergies. The deal has unusual political support: SMART-TD, the largest railroad union, formally backed the combination, and President Trump publicly endorsed it. The Surface Transportation Board (STB) rejected the initial merger application as procedurally incomplete; Union Pacific submitted notice of intent to refile in April 2026. Key opposition includes the Teamsters and passenger rail advocates. The STB's multi-year review process means final regulatory resolution is unlikely before 2027-2028.

→

$97.4B

Acquisition

Elon Musk Consortium → OpenAI

Artificial Intelligence / Technology

In February 2025, Elon Musk — alongside a16z and other venture backers — submitted an unsolicited $97.4 billion all-cash bid for OpenAI during its contentious restructuring from a nonprofit to a Public Benefit Corporation. OpenAI's board unanimously rejected the offer, with CEO Sam Altman calling it a strategic distraction. The bid was widely seen as below fair value: OpenAI completed its for-profit restructuring with SoftBank's $40 billion investment at a $260 billion valuation in late 2025. Musk's lawsuit alleging that Sam Altman and Microsoft deviated from OpenAI's founding nonprofit mission was cleared for a jury trial, which began March 30, 2026. A ruling against OpenAI could force structural changes to its for-profit conversion, potentially reopening restructuring scenarios. OpenAI faces approximately $14 billion in projected operating losses in 2026, renewing debate about whether a future strategic transaction remains plausible.

→

$34.5B

Acquisition

Charter Communications → Cox Communications

Telecommunications / Cable

Charter Communications is acquiring Cox Enterprises' cable, commercial fiber, and cloud communications businesses for $34.5 billion — the largest US cable consolidation since Charter's own Time Warner Cable acquisition in 2016. The FCC Wireline Competition Bureau approved the deal on 27 February 2026, with conditions including US job preservation, a $20/hour minimum starting wage for Cox workers, and onshoring of all offshore job functions within 18 months. The DOJ and states including New York and Connecticut have cleared the transaction. California's Public Utilities Commission is the sole remaining approval, with evidentiary hearings completed 20-24 April 2026. Charter has formally requested the California PUC to accelerate its review ahead of the September 15, 2026 federal merger condition deadline. The combined company will be the largest US internet service provider with over 37 million broadband subscribers, operating under the Cox name with the Spectrum consumer brand.

→

$17B

Acquisition

QXO → TopBuild

Industrials / Building Products

QXO announced a definitive agreement to acquire TopBuild Corp for approximately $17 billion on April 19, 2026 — the largest deal in the building products distribution sector in decades. TopBuild is the largest distributor and installer of insulation and related building products in North America. Under the terms, TopBuild stockholders can elect $505 in cash or 20.2 QXO shares per TopBuild share, with total consideration approximately 45% cash and 55% QXO stock. The $505 per share price represents a 23.1% premium to TopBuild's closing price on April 17, 2026. The deal has been unanimously approved by both boards. Upon closing, QXO will become the second largest publicly traded building products distributor in North America with over $18 billion in combined revenue and $2 billion in adjusted EBITDA. QXO CEO Brad Jacobs — who previously built XPO Logistics into a $35 billion company — has identified building products distribution as the platform for his next multi-decade rollup strategy, targeting $50 billion in sales. The acquisition is expected to close in Q3 2026.

→

$30B

Acquisition

Merck → Revolution Medicines

Pharmaceuticals / Oncology

The Financial Times reported in January 2026 that Merck is in advanced acquisition talks with Revolution Medicines, the South San Francisco-based oncology biotech, in a deal that could value RVMD at between $28 billion and $32 billion — potentially the largest biotech acquisition since Pfizer's $43 billion purchase of Seagen in 2023. Bloomberg subsequently confirmed the discussions. The strategic rationale is existential: Keytruda — Merck's flagship PD-1 cancer immunotherapy generating over $25 billion in annual revenue — faces biosimilar competition following US patent expiry in 2028. Revolution Medicines' RAS(ON) inhibitor platform targets KRAS-mutant cancers which account for approximately 25% of all human cancers. Lead assets RMC-6236 (pan-RAS) and RMC-6291 (KRAS G12C-selective) are in Phase 2/3 trials showing compelling early efficacy. Revolution Medicines shares rose approximately 40% on the initial FT report. No formal announcement as of May 2026.

→

$11.6B

Acquisition

Amazon → Globalstar

Technology / Satellite

Amazon agreed on 14 April 2026 to acquire satellite operator Globalstar in an $11.6 billion all-cash deal at $90 per share, enabling the creation of Amazon Leo — a direct-to-device (D2D) low Earth orbit satellite network. The acquisition gives Amazon proprietary spectrum and direct-to-device technology, replacing its previous reliance on Globalstar's satellite network under a commercial agreement. Amazon simultaneously announced a partnership with Apple for Amazon Leo to power satellite-based Emergency SOS and connectivity services for iPhone and Apple Watch, providing immediate large-scale commercial demand. Amazon's satellite deployment roadmap targets service launch in 2028. Close is expected in late 2026 or early 2027, pending FCC spectrum approval and standard antitrust clearance.

→

$5B

Acquisition

Gilead Sciences → Tubulis

Pharmaceuticals / Oncology

Gilead Sciences announced on April 7, 2026 that it will acquire Tubulis, a Munich-based clinical-stage biotech specialising in next-generation antibody-drug conjugates (ADCs), for $3.15 billion in upfront cash plus up to $1.85 billion in contingent milestone payments — a total deal value of up to $5 billion. The acquisition is expected to close in Q2 2026. Tubulis' two lead programs — TUB-040 (NaPi2b-directed, targeting ovarian cancer and NSCLC) and TUB-030 (5T4-directed) — are in Phase 1b/2 development showing a 59% overall response rate in platinum-resistant ovarian cancer. Following close, Tubulis will operate as a dedicated ADC research hub within Gilead, with its Munich site serving as the centre of Gilead's ADC innovation platform. The deal extends a significant M&A spree for Gilead, which has also agreed to pay $7.8 billion for Arcellx and $2.18 billion for Ouro Medicines in recent months, signalling a major strategic pivot toward oncology and immunology.

→

$6.3B

Acquisition

Silgan Holdings → Gerresheimer

Industrials / Pharmaceutical Packaging

US packaging company Silgan Holdings submitted a non-binding takeover approach for German pharmaceutical packaging group Gerresheimer, valuing the company at €41 per share — more than double its then-prevailing share price, at an implied enterprise value of approximately $6.3 billion. Gerresheimer's supervisory board rejected the bid on April 17, 2026, citing its intention to focus on resolving ongoing accounting irregularities and the sale of its US subsidiary Centor before pursuing any transaction. German financial watchdog BaFin has widened its examination of Gerresheimer's accounts; holders representing 96% of the €870 million promissory note volume agreed to extend the deadline for audited 2025 financial statements to September 30, 2026. Despite the rejection, analysts note that Gerresheimer remains a compelling strategic target — it is one of the world's largest manufacturers of glass and plastic packaging for the pharmaceutical industry, including primary packaging for GLP-1 drugs such as Ozempic and Mounjaro. With those markets growing rapidly, Silgan is expected to return with a revised offer once Gerresheimer's accounting clean-up is complete.

→

$8.3B

Acquisition

Denso → Rohm

Semiconductors / Automotive

Toyota-group automotive components giant Denso made a formal acquisition proposal for Kyoto-based power semiconductor manufacturer Rohm on March 6, 2026, in a deal valued at up to $8.3 billion via a full tender offer. Denso already holds approximately 5% of Rohm, a stake it acquired in September 2025 as a precursor to this approach. Both companies confirmed that discussions are underway, though 'no final decision has been made.' Rohm shares surged 18% on news of the proposal. The strategic rationale is the automotive industry's acute vulnerability to power semiconductor supply constraints exposed during the chip shortages of 2021-2023. Rohm is a Tier 1 global manufacturer of silicon carbide (SiC) power devices — the critical semiconductors governing battery charging and motor drive systems in electric vehicles. For Denso, vertical integration into SiC production would secure supply for Toyota Group's expanding EV lineup. METI (Japan's Ministry of Economy, Trade and Industry) has informally supported the combination.